Penserra Capital Management’s Alexion Pharmaceuticals Inc ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-8,052
| Closed | -$921K | – | 1156 |
|
|
2020
Q3 | $921K | Sell |
8,052
-1,087
| -12% | -$124K | 0.04% | 278 |
|
|
2020
Q2 | $1.03M | Sell |
9,139
-3,084
| -25% | -$346K | 0.05% | 265 |
|
|
2020
Q1 | $1.19M | Buy |
12,223
+246
| +2% | +$23.9K | 0.08% | 230 |
|
|
2019
Q4 | $1.29M | Buy |
11,977
+11,791
| +6,339% | +$1.27M | 0.08% | 262 |
|
|
2019
Q3 | $18K | Sell |
186
-969
| -84% | -$93.8K | ﹤0.01% | 752 |
|
|
2019
Q2 | $151K | Sell |
1,155
-17,820
| -94% | -$2.33M | 0.01% | 431 |
|
|
2019
Q1 | $2.58M | Buy |
+18,975
| New | +$2.58M | 0.21% | 88 |
|
|
2018
Q4 | – | Sell |
-2,300
| Closed | -$319K | – | 817 |
|
|
2018
Q3 | $319K | Sell |
2,300
-16,270
| -88% | -$2.26M | 0.02% | 362 |
|
|
2018
Q2 | $2.31M | Buy |
18,570
+16,746
| +918% | +$2.08M | 0.15% | 108 |
|
|
2018
Q1 | $203K | Buy |
1,824
+144
| +9% | +$16K | 0.02% | 253 |
|
|
2017
Q4 | $200K | Buy |
1,680
+264
| +19% | +$31.4K | 0.03% | 220 |
|
|
2017
Q3 | $199K | Buy |
1,416
+168
| +13% | +$23.6K | 0.05% | 203 |
|
|
2017
Q2 | $151K | Buy |
1,248
+144
| +13% | +$17.4K | 0.05% | 251 |
|
|
2017
Q1 | $133K | Sell |
1,104
-37
| -3% | -$4.46K | 0.01% | 273 |
|
|
2016
Q4 | $139K | Buy |
1,141
+347
| +44% | +$42.3K | 0.02% | 286 |
|
|
2016
Q3 | $96K | Buy |
794
+386
| +95% | +$46.7K | 0.01% | 281 |
|
|
2016
Q2 | $48K | Buy |
408
+139
| +52% | +$16.4K | 0.01% | 355 |
|
|
2016
Q1 | $36 | Buy |
269
+85
| +46% | +$11 | ﹤0.01% | 348 |
|
|
2015
Q4 | $35K | Buy |
+184
| New | +$35K | ﹤0.01% | 293 |
|